| Name | Title | Contact Details |
|---|
Immune Design is a clinical-stage immunotherapy company employing next-generation in vivo approaches designed to enable the body`s immune system to fight disease. The company`s technologies are engineered to activate the immune system`s natural ability to create tumor-specific cytotoxic T cells to fight cancer and other chronic disease. Immune Design`s clinical programs are the product of its two synergistic platforms: DCVexTM and GLAASTM.
Grand Rapids Clinical Oncology Program is a Grand Rapids, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ianacare is the best way for family caregivers to get the help and practical support they need (meals, rides, respite care, child care, pet care, house errands) from the people in their social circles, community, and co-workers who want to help. Get St...
Ameriplan is a Foley, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.